Trimethoprim-sulphamethoxazole in the treatment of urinary infection.
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002506:Cephalexin / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005194:Family Practice; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006761:Hospitals; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008826:Microbial Sensitivity Tests; D010919:Placebos; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D014295:Trimethoprim / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D010919:Placebos; D011743:Pyrimidines; D000667:Ampicillin; D014295:Trimethoprim; D013420:Sulfamethoxazole; D002506:Cephalexin